• Frank Grosveld, PhD

    Harbour Antibodies' scientific founder
    Academy Professor of Cell Biology at Erasmus Medical Center, Rotterdam
    Member of Royal Netherlands Academy of Arts and Sciences
    Fellow of the Royal Society
    Winner of Louis-Jeantet Prize for Medicine
    Knight in the Order of the Netherlands Lion
    Discoverer of hemoglobin locus control region (LCR)
    Numerous peer-reviewed research papers and patents
    Inventor/Developer of 4C Technology (Chromosome Conformation Capture on Chips)
    Co-founder of four companies

    PhD from McGill University, Quebec, Canada

  • Richard A. Flavell, PhD, FRS

    Sterling Professor of Immunobiology at Yale University School of Medicine
    Howard Hughes Medical Institute Investigator
    Fellow of the Royal Society
    Member of the National Academy of Sciences

    Previously,
    President and Chief Scientific Officer of Biogen Research Corporation
    Numerous awards, honors, and lectures
    Over 1,000 peer reviewed publications

    PhD in Biochemistry from the University of Hull, England
    Field of expertise: Innate and adaptive immunity, T cell tolerance, activation, and differentiation

  • Robert Kamen, PhD

    Entrepreneur in Residence, Third Rock Ventures
    Member, Board of Directors, Neon Therapeutics, Jounce Therapeutics, EpiMab and Lycera

    Previously,
    President of Abbott Bioresearch Center and its predecessor, BASF Bioresearch. Oversaw the discovery and production of Humira®(adalimumab), one of the world's top selling pharmaceuticals
    Senior VP Scientific Affairs, Genetics Institute, Inc
    Biopharm Investment Board, GlaxoSmithKline
    Member, Board of Directors, Harbour Antibodies

    PhD in Biochemistry and Molecular Biology from Harvard University

  • Robert Kramer, PhD

    CSO of SalvaRx Therapeutics and Sonnet Biotherapeutics

    Previously,
    VP and Global Head Oncology Discovery, Johnson & Johnson
    VP Oncology and Immunology Drug Discovery & Princeton Research Site Head, Bristol-Myers Squibb
    Led and oversaw Oncology and Immunology programs that received FDA approvals for treating patients with chronic myeloid leukemia, breast cancer and melanoma
    Director, Oncology and Immunology Research, Lederle-Wyeth
    Assistant Professor at Harvard Medical School
    Staff Fellow NIH

    PhD in Pharmacology from the University of Vermont

  • Peter Moesta, PhD

    CEO, Adello Biologics, LLC

    Previously,
    Senior VP of Biologics Development and Operations at Bristol-Myers Squibb. Oversaw the development, production and worldwide launch of Opdivo® (novlumab) and Yervoy® (ipilimumab)
    VP of Biologics Manufacturing for Abbott Laboratories, guided the manufacturing process and led the CMC effort to obtain approval for Humira®
    VP of Biologics Process Development and Operations for BASF Bioresearch Corporation

    PhD in Biochemistry from the University of Freiburg in Germany